Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Development of a novel IGRA assay to test T cell responsiveness to HBV antigens in whole blood of chronic Hepatitis B patients

Fig. 3

HBeAg + CHB patients show weaker cytokine responses against HBcAg and HBsAg than HBeAg- CHB patients. (a) – (d) n = 40 NUC treatment naïve CHB patients with n = 6 HBeAg + and n = 34 HBeAg-. n = 32 NUC treated CHB patients, with n = 6 HBeAg + and n = 26 HBeAg-. (e) – (h) n = 40 NUC treatment naïve CHB patients with n = 10 HBV-DNA ≤50 IU/ml and n = 30 HBV-DNA >50 IU/ml. n = 32 NUC treated CHB patients, with n = 22 HBV-DNA ≤50 IU/ml and n = 10 HBV-DNA >50 IU/ml. Every patient was tested against HBV antigens HBcAg and HBsAg. (a), (b), (e) and (f) IFNγ, (c), (d), (g) and (h) IL2, respectively. Negative control values were deducted from the antigen induced responses. Lower limit of detection (background + 3x S.D.) was at 2 – 5 pg/ml for IFNγ and IL2. All values are given as mean concentration pg/ml ± S.E.M. Unpaired t-test, following symbol pinpoints significant differences: *. One symbol equals 0.05, two symbols 0.01, three symbols 0.001, n.s. not significant

Back to article page